Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) Stock Technical Analysis & Trading Signals
Live technical indicators, trading signals, and momentum insights for Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (HKSE:9989.HK).
Disclaimer for Technical Analysis Page
The technical indicators and trading signals shown on this page are for informational purposes only and do not constitute financial advice. Stock market investments involve risk, and past performance is not a guarantee of future results. Always conduct your own research or consult a licensed financial advisor before making investment decisions.Read our Full Disclaimer9989.HK Technical Analysis Summary
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. stock currently shows a bullish trend, supported by momentum and strong buying pressure.
Overall, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. remains neutral, with indicators showing mixed momentum.
RSI (14): 50.11
Stochastic %K: 47.98
Williams %R: -29.55
Rate of Change (ROC): -1.55
Takeaway:Shenzhen Hepalink Pharmaceutical Group Co., Ltd. shows neutral momentum, with indicators pointing to indecision.
MACD: -0.08
ADX: 23.68
ATR (14): 0.13
CCI (14): 48.57
Takeaway:Shenzhen Hepalink Pharmaceutical Group Co., Ltd. shows a firm trend supported by momentum, though one signal suggests caution.
Takeaway:Shenzhen Hepalink Pharmaceutical Group Co., Ltd. trades around the middle band, reflecting balanced price action.
Takeaway:Shenzhen Hepalink Pharmaceutical Group Co., Ltd. trades above the trend line, showing healthy momentum within the channel.
Overall Takeaway:9989.HK shows mixed signals in money flow analysis.
Bullish Signals
RSI above 50 → positive momentum from buyers.
ADX above 20 → strong underlying trend.
Price trading above middle Bollinger Band → mid-term support intact.
MFI below 80 → room for more buying without overbought risk.
Bearish Signals
No significant bearish signals detected.
Overall Recommendation:Technical indicators for Shenzhen Hepalink Pharmaceutical Group Co., Ltd. are mixed, suggesting a Hold or wait-and-see approach.